Radiopharm Theranostics Launches US$4.1M Direct Offering and Up to A$12.7M Australian Placement, Totaling ~US$17.7M
RADX sits 19% above its 52-week low of $3.62.
Summary
Radiopharm Theranostics announced a concurrent US$4.1 million registered direct offering and up to A$12.7 million Australian placement and share purchase plan, raising up to ~US$17.7 million to fund clinical development.
Key Events · Financing and Capital Events · RADX
-
US$4.1M Direct Offering at Discount
The company is issuing 1,281,646 ADSs at US$3.16 per ADS, a 26% discount to the current US$4.29 price, raising US$4.1 million before fees.
-
Warrants Attached to US Offering
Investors receive unregistered warrants to purchase up to 1,281,646 ADSs at US$3.79, exercisable after shareholder approval, expiring July 2029.
-
Australian Placement and Share Purchase Plan
Up to A$12.7 million (US$8.9 million) could come from an Australian placement (A$6.7M firm commitments) and a share purchase plan (up to A$6M), with options at A$0.018.
-
Total Potential Raise ~US$17.7M
Combined US and Australian components could bring in up to US$17.7 million, significantly extending the cash runway for clinical programs.
Analysis · RADX · Life Sciences
To fund its next clinical milestones, Radiopharm Theranostics is tapping the market for up to US$17.7 million through a multi-pronged offering. The package includes a US$4.1 million registered direct offering of ADSs priced at US$3.16—a 26% discount to the current US$4.29—alongside up to A$12.7 million (US$8.9 million) from an Australian placement and share purchase plan. The deep discount and attached warrants and options signal an urgent need for capital, but the proceeds are earmarked for a registrational study and other clinical work, which is critical for a clinical-stage biotech. Coming just two days after positive Phase 2b data, the raise suggests the company is seizing the momentum to extend its runway. While a concurrent ATM program filed yesterday adds to the dilution overhang, this direct raise locks in immediate cash.
At the time of this filing, RADX was trading at $4.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.9M. The 52-week trading range was $3.62 to $16.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.